Venaxis (APPY)

1.67 +0.02  +1.21%  May 21, 5:01PM
Add to Watchlists Create an Alert

Venaxis R&D Expense Quarterly:

1.215M for Dec. 31, 2012
View Full Chart

Venaxis R&D Expense Quarterly Chart

    Venaxis Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 1.215M
    Sept. 30, 2012 1.066M
    June 30, 2012 0.8806M
    March 31, 2012 0.6766M
    Dec. 31, 2011 1.293M
    Sept. 30, 2011 1.645M
    June 30, 2011 1.456M
    March 31, 2011 1.272M
    Dec. 31, 2010 1.714M
    Sept. 30, 2010 1.043M
    June 30, 2010 1.311M
    March 31, 2010 2.044M
    Dec. 31, 2009 2.780M
    Sept. 30, 2009 2.275M
    June 30, 2009 2.242M
    March 31, 2009 1.416M
    Dec. 31, 2008 1.701M
    Sept. 30, 2008 1.963M
    June 30, 2008 1.563M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
       
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    APPY R&D Expense Quarterly Benchmarks

    Companies
    CombiMatrix Corporation 0.297M
    Agilent Technologies 179.00M
    BG Medicine -0.08M

    APPY R&D Expense Quarterly Rankings

    Overall 84th percentile
    1211 of 8002
    Sector 46th percentile
    366 of 684 in Healthcare
    Industry 60th percentile
    26 of 65 in Diagnostics & Research

    APPY R&D Expense Quarterly Range, Past 5 Years

    Minimum 0.6766M Mar 2012
    Maximum 2.780M Dec 2009
    Average 1.556M